BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, Collino M. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. Br J Pharmacol 2020;177:4921-30. [PMID: 32776354 DOI: 10.1111/bph.15229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Saeedi-boroujeni A, Nashibi R, Ghadiri AA, Nakajima M, Salmanzadeh S, Mahmoudian-sani M, Hanafi MG, Sharhani A, Khodadadi A. Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial. Archives of Medical Research 2022. [DOI: 10.1016/j.arcmed.2022.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yin L, Zhao H, Zhang H, Li Y, Dong Y, Ju H, Kong F, Zhao S. Remdesivir Alleviates Acute Kidney Injury by Inhibiting the Activation of NLRP3 Inflammasome. Front Immunol 2021;12:652446. [PMID: 34093539 DOI: 10.3389/fimmu.2021.652446] [Reference Citation Analysis]
3 Yadav UCS. Vaccines and drugs under clinical trials for prevention and treatment of COVID-19. Virusdisease 2021;:1-7. [PMID: 33778130 DOI: 10.1007/s13337-020-00650-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yong Y, Zhang L, Hu Y, Wu J, Yan L, Pan Y, Tang Y, Yu L, Law BY, Yu C, Zhou J, Li M, Qin D, Zhou X, Wu A. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109093] [Reference Citation Analysis]
5 Kow CS, Ramachandram DS, Hasan SS. Colchicine for COVID-19: Hype or hope? Eur J Intern Med 2021:S0953-6205(21)00387-3. [PMID: 34810043 DOI: 10.1016/j.ejim.2021.11.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Keller K, Sagoschen I, Schmitt VH, Sivanathan V, Espinola-klein C, Lavie CJ, Münzel T, Hobohm L. Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19. Front Endocrinol 2022;13:876028. [DOI: 10.3389/fendo.2022.876028] [Reference Citation Analysis]
7 Yepiskoposyan H, Peitsch MC, Talikka M, Li J. Causal Biological Network Model for Inflammasome Signaling Applied for Interpreting Transcriptomic Changes in Various Inflammatory States. International Journal of Inflammation 2022;2022:1-13. [DOI: 10.1155/2022/4071472] [Reference Citation Analysis]
8 Vassileva S, Mateeva V, Drenovska K. Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction? Clin Dermatol 2021;39:430-45. [PMID: 34518001 DOI: 10.1016/j.clindermatol.2021.01.020] [Reference Citation Analysis]
9 Zeng X, Liu D, Wu W, Huo X. PM2.5 exposure inducing ATP alteration links with NLRP3 inflammasome activation. Environ Sci Pollut Res Int 2022;29:24445-56. [PMID: 35064883 DOI: 10.1007/s11356-021-16405-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu D, Zeng X, Ding Z, Lv F, Mehta JL, Wang X. Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. Front Pharmacol 2021;12:699949. [PMID: 34512335 DOI: 10.3389/fphar.2021.699949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sánchez KE, Rosenberg GA. Shared Inflammatory Pathology of Stroke and COVID-19. Int J Mol Sci 2022;23:5150. [PMID: 35563537 DOI: 10.3390/ijms23095150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Manolis AS, Manolis AA, Manolis TA, Apostolaki NE, Melita H. COVID-19 infection and body weight: A deleterious liaison in a J-curve relationship. Obes Res Clin Pract 2021;15:523-35. [PMID: 34799284 DOI: 10.1016/j.orcp.2021.10.006] [Reference Citation Analysis]
13 Wijeratne T, Gillard Crewther S, Sales C, Karimi L. COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception-A Systematic Review. Front Neurol 2020;11:607221. [PMID: 33584506 DOI: 10.3389/fneur.2020.607221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
14 Tang Y, Hu L, Liu Y, Zhou B, Qin X, Ye J, Shen M, Wu Z, Zhang P. Possible mechanisms of cholesterol elevation aggravating COVID-19. Int J Med Sci 2021;18:3533-43. [PMID: 34522180 DOI: 10.7150/ijms.62021] [Reference Citation Analysis]
15 Kow CS, Lee LH, Ramachandram DS, Hasan SS, Ming LC, Goh HP. The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials. Immun Inflamm Dis 2022;10:255-64. [PMID: 34970856 DOI: 10.1002/iid3.562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zeng J, Xie X, Feng XL, Xu L, Han JB, Yu D, Zou QC, Liu Q, Li X, Ma G, Li MH, Yao YG. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. EBioMedicine 2022;75:103803. [PMID: 34979342 DOI: 10.1016/j.ebiom.2021.103803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
17 Saeedi-Boroujeni A, Mahmoudian-Sani MR, Nashibi R, Houshmandfar S, Tahmaseby Gandomkari S, Khodadadi A. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol Immunotoxicol 2021;43:247-58. [PMID: 34015982 DOI: 10.1080/08923973.2021.1925293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Islamuddin M, Mustfa SA, Ullah SNMN, Omer U, Kato K, Parveen S. Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection. Inflammation 2022. [PMID: 35953688 DOI: 10.1007/s10753-022-01651-y] [Reference Citation Analysis]
20 Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, Collino M. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. Br J Pharmacol 2020;177:4921-30. [PMID: 32776354 DOI: 10.1111/bph.15229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]